KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Receivables (2016 - 2025)

Thermo Fisher Scientific's Receivables history spans 17 years, with the latest figure at $10.6 billion for Q4 2025.

  • For the quarter ending Q4 2025, Receivables rose 9.77% year-over-year to $10.6 billion, compared with a TTM value of $10.6 billion through Dec 2025, up 9.77%, and an annual FY2025 reading of $10.6 billion, up 9.77% over the prior year.
  • Receivables for Q4 2025 was $10.6 billion at Thermo Fisher Scientific, roughly flat from $10.5 billion in the prior quarter.
  • The five-year high for Receivables was $10.6 billion in Q4 2025, with the low at $6.3 billion in Q3 2021.
  • Average Receivables over 5 years is $9.1 billion, with a median of $9.4 billion recorded in 2022.
  • Year-over-year, Receivables soared 41.59% in 2022 and then fell 0.59% in 2024.
  • Tracing TMO's Receivables over 5 years: stood at $8.9 billion in 2021, then rose by 5.39% to $9.4 billion in 2022, then increased by 2.51% to $9.7 billion in 2023, then fell by 0.39% to $9.6 billion in 2024, then grew by 9.77% to $10.6 billion in 2025.
  • Per Business Quant, the three most recent readings for TMO's Receivables are $10.6 billion (Q4 2025), $10.5 billion (Q3 2025), and $10.0 billion (Q2 2025).